Human Microbiome Sequencing Market Key Players Analysis Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Human Microbiome Sequencing Market by (Product Type (Kits And Assays, Instruments, And Software), Technology (Sequencing By Synthesis, Sequencing By Ligation And Other Next-Generation Sequencing Technologies), Traditional Sequencing Technologies (Pyrosequencing And Sanger Sequencing) And Other Sequencing Technology. Application (Disease Diagnosis (Gastrointestinal Diseases, Metabolic Diseases, Oncology, Infectious Diseases, Neurological Diseases And Other Diseases), Drug Discovery, Consumer Wellness, Omics Analysis (Genome Analysis, Metabolome Analysis, Transcriptome Analysis And Other Omics Analysis) And Other Application), End-User (Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, And Other End Users) - Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

The global human microbiome sequencing market is estimated to exhibit a CAGR of 20.8% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1380

The term "human microbiome" refers to the diverse community of microorganisms, including bacteria, bacteriophages, fungi, protozoa, and viruses, that inhabit the human body. These microbial cells outnumber human cells by a factor of ten and collectively account for approximately 2-3 kilograms of body weight. The market for human microbiome sequencing is experiencing significant growth, driven by advancements in genomics, proteomics, and metabolomics, along with the evolution of next-generation sequencing (NGS) technologies. Additionally, increasing focus on human microbiome therapy as a promising therapeutic target is further contributing to market expansion.

The demand for human microbiome sequencing is also being fueled by its growing application in early disease detection and diagnosis, as well as the reduction in sequencing costs. Moreover, the market is benefiting from heightened research collaborations, increased funding in microbiome-related studies, and the need for investigational new drug (IND) applications, particularly for fecal microbiota. The global expansion of genomic research is further propelling the forecasted growth of the human microbiome sequencing market, supported by a surge in genomic R&D initiatives.

List of Prominent Players in the Human Microbiome Sequencing Market:
• Baseclear B.V.
• Beijing Genomics Institute (BGI) Genomics Co., Ltd
• Charles River Laboratories International Inc.
• Clinical Microbiomics A/S
• Eurofins Scientific SE
• GENEWIZ, Inc.
• Illumina, Inc.
• Novogene Corporation
• OraSure Technologies, Inc.
• Oxford Nanopore Technologies, Inc.
• Pacific Biosciences of California, Inc.
• QIAGEN N.V.
• Second Genome, Inc.
• Thermo Fisher Scientific Inc.
• Viome, Inc.
• CosmosID
• Leucine Rich Bio Pvt. Ltd.
• Microba
• Microbiome Insights Inc.
• Molzym GmbH & Co. KG

Market Dynamics:
Drivers-
The human gut microbiota plays a pivotal role in enhancing the effectiveness of pharmaceuticals. Research has demonstrated that maintaining an optimal microbial balance within the human body can contribute to the treatment of a variety of diseases. This connection between specific disease states and microbial populations opens up new opportunities for drug and vaccine development. Microorganisms are also significant sources of enzymes, making them valuable for therapeutic applications, particularly in the search for novel treatments. With numerous small, innovative companies operating within the market, there are substantial growth opportunities for key industry players to acquire these entities and advance microbiome research in the pursuit of discovering new drugs and drug targets for conditions such as obesity, liver diseases, diabetes, and metabolic disorders. Strategic partnerships and collaborations are increasingly prioritized by leading market participants as they seek to expand their product portfolios through enhanced research and development initiatives.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Challenges:
Probiotics have not been granted approval by the FDA as live biotherapeutic products, which are biological products, excluding vaccines, that contain living organisms and are used for the treatment or prevention of human diseases. While probiotic-containing foods, including dietary supplements, remain FDA-regulated and are legally marketed, they cannot be used to treat, prevent, or mitigate any illnesses. The FDA is considering revising its regulatory framework regarding probiotics. Additionally, genetically engineered microorganisms may face a distinct or entirely new set of regulatory challenges. Furthermore, the current methods for identifying microbial indicators for diagnostic purposes require comparisons with parallel control groups of healthy individuals to ensure their effectiveness. Identifying the most suitable microbe for specific applications presents a significant challenge, complicating the selection of the appropriate microbial chassis for microbiota-based treatments.

Regional Trends:
North America currently leads the human microbiome sequencing market, driven by the region's strong healthcare infrastructure, substantial investments from major companies in developing innovative devices, drug development processes, and research activities. This dominance is also supported by advancements in next-generation sequencing (NGS) technologies and the rising incidence of lifestyle-related health conditions. For example, Illumina Inc., a leading American company, has highlighted that advancements in NGS have facilitated high-profile collaborative initiatives such as the Human Microbiome Project and MetaHIT, which have utilized NGS as their primary tool to generate extensive data on the human microbiome. In contrast, the Asia-Pacific region is expected to experience significant growth during the forecast period, driven by the expansion of related institutions and an increasing focus on microbiome research. The rising prevalence of lifestyle diseases, growing awareness of preventive healthcare, increased funding for microbiome research, and the expansion of microbiome-related research and clinical activities are key factors propelling the growth of the regional market.

Recent Developments:
• In September 2021, PhenoBiome announced that its first human gut microbiome assay would be available through Genetic Direction, a Dallas-based distributor of genetics-based health management solutions. Clinical Enterprise, Inc., a Eurofins Scientific subsidiary, will perform the assays in its CLIA- and CAP-certified laboratory.
• In July 2021, Seres Therapeutics Inc. and Nestlé Health Science agreed to collaborate on the commercialization of SER-109, an experimental oral microbiome treatment for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada. If it is approved, SER-109 will be the first FDA-approved microbiome treatment.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1380

Segmentation of Human Microbiome Sequencing Market-
By Product Type
• Kits and Assays
• Instruments
• Software
By Technology
• Next-Generation Sequencing
o Sequencing by Synthesis
o Sequencing by Ligation
o Other Next-Generation Sequencing Technologies
• Traditional Sequencing Technologies
o Pyrosequencing
o Sanger Sequencing
• Other Sequencing Technology
By Application
• Disease Diagnoses
o Gastrointestinal Diseases
o Metabolic Diseases
o Oncology
o Infectious Diseases
o Neurological Diseases
o Other Diseases
• Drug Discovery
• Consumer Wellness
• Omics Analysis
o Genome Analysis
o Metabolome Analysis
o Transcriptome Analysis
o Other Omics Analysis
• Other Application
By End User
• Research and Academic Institutions
• Pharmaceutical and Biotechnology Companies
• Other End Users
By Region-
• North America-
o US
o Canada
o Mexico
• Europe-
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific-
o China
o Japan
o India
o South Korea
o South East Asia
o Rest of Asia Pacific
• Latin America-
o Brazil
o Argentina
o Rest of Latin America
• Middle East & Africa-
o GCC Countries
o South Africa
o Rest of the Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.